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http:WHAT THIS PAPER ADDS
Despite their widespread use, the evidence to support many interventions in the diabetic foot derives from
studies of poor quality. We highlight the need for separate reporting of outcomes in patients with diabetes
undergoing revascularisation for critical limb ischaemia and challenge current classiﬁcation systems for
peripheral arterial disease in this cohort. The review focuses on evidence-based strategies for diabetic foot
ulceration (DFU) to promote healing and preserve life and limb. We emphasize the importance of referring all
patients presenting with DFU to a multidisciplinary team involving vascular surgeons and interventional
radiologists.Diabetic foot ulceration (DFU) is associated with high morbidity and mortality, and represents the leading cause
of hospitalization in patients with diabetes. Peripheral arterial disease (PAD), present in half of patients with DFU,
is an independent predictor of limb loss and can be difﬁcult to diagnose in a diabetic population. This review
focuses on the evidence for therapeutic strategies in the management of patients with DFU. We highlight the
importance of timely referral of patients presenting with a new foot ulcer to a multidisciplinary team, which
includes vascular surgeons and interventional radiologists.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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betes mellitus (DM) has resulted in an inevitable rise in
diabetes-related complications. In 2011, there were an
estimated 366 million adults with diabetes worldwide and
projections indicate this ﬁgure will rise to 552 million by
2030.1 Amputation is a largely preventable complication of
diabetes and >85% of major amputations in patients with
diabetes are preceded by foot ulceration.2 Despite evidence
to suggest that targeted interventions resulting from
multidisciplinary care can reduce limb loss, progress to date
has been slow.3 Whilst the number and incidence of
amputations have fallen in an ageing population without
diabetes, those in patients with type 2 diabetes have risen
in some countries.4 Twenty years on from the St Vincent’s
Declaration,5 attempts to achieve 5-year targets to halve
the number of lower limb amputations in patients withTo access continuing medical education questions on this
please go to www.vasculareducation.com and click on ‘CME’
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//dx.doi.org/10.1016/j.ejvs.2013.02.014evidence for the management of peripheral arterial disease
(PAD) and the diabetic foot, highlighting recent guidelines
produced by the International Working Group on the Dia-
betic Foot (IWGDF) and the European Society of Vascular
Surgery (ESVS).6,7
Foot lesions carry high morbidity and mortality and
represent the most common cause of hospitalization in
patients with diabetes. The lifetime risk of foot ulceration in
patients with diabetes lies between 15% and 25%,8,9 with
an annual incidence of around 2%.10 The risk of a person
with diabetes undergoing a lower extremity amputation is
estimated to be 23 times that of a person without dia-
betes,11 and the National Diabetes Audit estimates that
every 7 out of 10 000 people with diabetes in England and
Wales underwent a major amputation in 2008e2009. In
2010e2011 there were 72 459 hospital admissions for
diabetes-related foot complications,12 at an estimated cost
of between £639 million and £662 million to the National
Health Service in England and Wales.13
PAD is an independent risk factor for subsequent ulcer-
ation and limb loss in diabetes. It is present in 50% of
patients with diabetic foot ulceration (DFU), a proportion
which may be increasing.14,15 Those with DFU and PAD are
less likely to heal and more likely to require amputation
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that PAD is identiﬁed in all patients with diabetes.PATHOLOGY IN DFU
The aetiology of DFU is multifactorial and involves
a complex interplay between distal polyneuropathy (motor,
sensory and autonomic), abnormal foot anatomy, functional
changes in the microcirculation and PAD. The pathway to
ulceration typically follows abnormal loading or trauma of
the painless neuropathic foot, which may be poorly
perfused due to PAD, rendering it less able to heal. Both
ulceration and infection in the foot will increase the
demand for oxygen and, as such, vascular intervention may
be required to achieve healing in cases where objective
measures of perfusion suggest that PAD is only of mild
severity. The wound repair process may be further impaired
by virtue of various biological factors inherent to diabetes,
including impaired humoral immunity and abnormal
inﬂammatory responses.16,17
Early descriptions of diabetes as an occlusive small vessel
disease were disproven by histological staining of ampu-
tated limbs,18 and subsequently by arterial casting studies.
This led to the identiﬁcation of several functional abnor-
malities of the microvasculature including an increase in
arterio-venous shunting and impaired vasoreactivity.19 In
patients with type 2 diabetes these changes lead to capil-
lary hypoperfusion, probably further impairing wound
healing.20 Furthermore, the development of collateral
vessels is impaired in patients with diabetes.21 Conse-
quently arterial occlusions may result in more severe
perfusion deﬁcits in those with diabetes compared to those
without diabetes. The distribution of PAD in patients with
diabetes is characteristically distal and diffuse, with
a greater prevalence of crural disease and long arterial
occlusions.22e24 The distribution of PAD in diabetes may
relate to the presence of somatic neuropathy, which has
been implicated in the development of medial arterial
calciﬁcation.25Figure 1. Schematic estimate of the probability of healing of foot
ulcers and minor amputations in relation to ankle blood pressure,
toe blood pressure, and transcutaneous oxygen pressure (TcPo2)
based on selected reports. From Bakker K, Apelqvist J, Schaper NC.
Practical guidelines on the management and prevention of the
diabetic foot 2011. Diabetes Metab Res Rev, 2012;28 Suppl
1:225e31.DIAGNOSIS OF PAD
Identiﬁcation of PAD in patients with diabetes may be
difﬁcult because symptoms and signs are frequently masked
by co-existing distal symmetrical polyneuropathy. Further-
more, most patients with DFU present to primary care,
podiatry or internal medicine clinicians who are not experts
in the diagnosis of PAD. IWGDF guidelines suggest that, in
addition to a thorough history for symptoms of arterial
insufﬁciency, all patients with a diabetic foot ulcer should
undergo hand-held Doppler evaluation of both pedal pul-
ses, measurement of ABI and, in cases of diagnostic
uncertainty, measurement of toe-brachial index (TBI) or
transcutaneous pressure of oxygen (TcPO2).
6 Importantly
these screening tools, whilst highly sensitive in the non-
diabetic population, may be less efﬁcacious in diabetes,
especially in the presence of peripheral and autonomic
neuropathy.26,27 Those patients with signs and symptoms of
PAD, including claudication, rest pain, absent foot pulses,
monophasic Doppler signals, ABI <0.9 or TBI <0.7 should
be referred to a vascular surgeon for imaging of the vascular
tree and to consider revascularisation options as part of an
interdisciplinary approach. However, vascular specialists
might wish to be involved in the diagnosis and management
of any new patient presenting with DFU given that the
majority will have PAD.
Once a diagnosis of PAD is established, it is important to
assess the severity of the perfusion deﬁcit and what impact
this may have on ulcer healing. With respect to ankle
pressures, an ABI of <0.6 corresponds to a signiﬁcant
impairment in wound healing (Fig. 1).28 A low probability of
wound healing due to poor perfusion should prompt
further investigations to establish the distribution of PAD.
Guidelines published by the National Institute for Clinical
Excellence (NICE) in the UK recommend offering duplex
ultrasound as ﬁrst-line imaging to all people with PAD
where revascularisation is being considered.29 Evaluation of
the below-knee vessels is particularly important in patients
with diabetes and the sensitivity of DUS for detecting
a high-grade stenosis (50%) are 90% for the anterior and
posterior tibial arteries and 82% for the peroneal artery.30
Although DUS is non-invasive and relatively inexpensive
compared with other imaging modalities, its reliability is
dependent on operator expertise. The evaluation of below-
knee vessels with haemodynamic parameters alone does
not provide adequate information for preoperative plan-
ning, but may serve as a useful and intermediate adjunct to
other, more invasive modalities.31
Digital subtraction angiography (DSA) remains the gold
standard imaging modality for evaluating the distribution of
PAD when revascularisation is planned and has the advan-
tage of allowing simultaneous endovascular intervention. Its
main drawback in patients with diabetes and a high prev-
alence of renal insufﬁciency is the risk of contrast-induced
nephropathy. As a precaution, patients with renal impair-
ment should receive peri-procedural intravenous volume
expansion and metformin should be stopped prior to DSA
as it may cause a lactic acidosis.32 The visualization of pedal
J.R.W. Brownrigg et al. 675vessels with DSA may be limited in patients with severe
occlusive disease, where the concentration of contrast falls
short of the sensitivity threshold. In such instances, a hand-
held Doppler probe can be useful in unmasking pedal target
arteries not visible on DSA.
Contrast-enhanced magnetic resonance angiography (CE-
MRA) is a low-invasive modality capable of imaging calciﬁed
vessels without artifact and avoids the need for nephrotoxic
iodinated contrast. Temporally resolved hybrid CE-MRA
using an aortoiliac and femoral bolus-chase achieves the
best diagnostic performance. In a study of patients with
diabetes, the sensitivity and speciﬁcity for time-resolved CE-
MRA of crural vessels was 79% and 90% respectively.33
Disadvantages of MRA include limited spatial resolution
and a relative contraindication for the use of gadolinium in
patients with severe renal insufﬁciency (creatinine clear-
ance <30 ml/min), which has been linked to the develop-
ment of nephrogenic systemic ﬁbrosis.34 In addition, the
occurrence of stent artefacts in MRA limit its use for the
detection of in-stent stenosis.
Computed tomography angiography (CTA) should be
offered where MRA is contraindicated,29 and has several
advantages over MRA with respect to the speed of exami-
nation and spatial resolution. It is limited by image inter-
ference from calciﬁed arteries, which can make
interpretation difﬁcult. A systematic review comparing
sensitivity and speciﬁcity of DUS, contrast enhanced MRA
and multidetector-row CTA reported similar accuracies
across these modalities for detecting high-grade stenoses
above and below the knee.35
REVASCULARISATION
Data from the EURODIALE Study (a prospective study of
newly presenting patients with DFU to 14 experienced
European diabetic foot centres) would seem to suggest that
many patients are not having vascular imaging nor being
considered for revascularisation.36 Of those patients with
severe ischaemia (ABPI <0.5) appropriate vascular imaging
was performed in just 56%, and only 43% of those imaged
were revascularised. It is quite possible that the picture is
even bleaker for patients outside specialist centres. Retro-
spective review of the Eurodiale data suggests there are
various reasons why revascularisation was not performed,
including spontaneous wound healing, poor clinical condi-
tion of the patient or surgeon preference.
The decision to revascularise the ulcerated foot is
complex. Multiple factors inﬂuence wound healing in dia-
betes in addition to PAD. Patients with mild PAD and
adequate perfusion measurements (ABI 0.6, TcPO2
>50 mmHg) should be initially managed with optimal
wound care (debridement, treatment of infection and off-
loading) and a 6-week period of observation. There is
level II evidence to suggest the healing response to ‘best
medical therapy’ during this period gives a good indication
as to the adequacy of perfusion.37 In large ulcers and in
those with the combination of PAD and infection, the ex-
pected outcome of conservative treatment is poor (level I
evidence) and earlier vascular intervention may berequired. If it is felt that PAD is contributing towards
impaired wound healing then patients, if ambulatory,
should be considered for revascularisation with the excep-
tion of the severely frail or functionally impaired and those
with an unsalvageable foot. Importantly, where PAD is likely
to compromise healing of a major amputation wound,
interventions to optimize inﬂow should be considered.
Revascularisation in patients with diabetes can be tech-
nically difﬁcult by virtue of the distal distribution of disease,
impaired collateral formation and vessel calciﬁcation. Data
pooled by the IWGDF from 19 studies of patients with DFU
and PAD showed a median limb salvage rate of 85% at 1-
year.38 Half of patients with DFU and PAD can expect to
be alive at 5-years and mortality rises to 50% in 2-years
following a major amputation.39 Patients with co-existing
chronic kidney disease (CKD) fare worse and the severity
of CKD has been shown to correspond with poor outcomes
and mortality following revascularisation.40
There are no randomized trial data comparing surgical
bypass and endovascular interventions in selected patients
with diabetes or infrageniculate disease, however, in
patients with diabetes and an ischaemic foot ulcer, these
techniques appear to offer equivalent outcomes where
revascularisation is successful.41,42 The BASIL trial,43 which
randomized patients with severe limb ischaemia (rest pain
or tissue loss for >2 weeks) to bypass or balloon-
angioplasty, demonstrated similar outcomes in terms of
health-related quality of life and amputation-free survival,
although less than half of randomized patients had diabetes
and no sub-group analyses were performed. Endovascular
techniques performed under local anaesthesia are lower-risk
than bypass surgery and cost considerably less; however, an
increased re-intervention rate following angioplasty in the
BASIL trial reduced any overall cost difference.44 Data from
the BASIL trial suggest they are also associated with lower
short-term morbidity and, as such, endovascular therapy is
probably justiﬁed as the initial approach to restoring
perfusion. Surgical bypass has the advantage of increased
durability when autologous vein is used but patients with
multiple comorbidities and a short life expectancy (6e12
months) are unlikely to realize this beneﬁt.
The distal distribution of PAD in diabetes has brought
about innovation and development in both endovascular
techniques and open bypass surgery. Distal endovascular
interventions and distal origin bypass grafts arising from the
SFA, popliteal or crural vessels show good outcomes in
selected patients. Identifying the optimal artery for angio-
plasty or run-off vessel for bypass requires careful scrutiny
of anatomic and haemodynamic factors and some authors
advocate revascularisation based on the angiosome model
of perfusion, where the target artery corresponds to the
area of tissue loss.45 It is important to note that angiosomes
are a representation of normal anatomy and changes to the
collateral circulation that result from PAD mean the success
of this technique in reconstructive surgery will not neces-
sarily extrapolate to revascularization in cases of DFU. The
available evidence for the angiosome concept is limited, but
it does seem a logical step to achieve healing in diabetic
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angiosome-guided endovascular techniques, rates of limb
salvage and healing at 1-year were encouraging, at 91% and
85% respectively.46 Interestingly, a meta-analysis of 31
studies reporting results of popliteal to distal vein bypasses
has demonstrated greater limb salvage rates than corre-
sponding patency data.41 Primary patency at 1 and 5-years
was 82% and 63% respectively with corresponding foot
salvage rates of 89% and 78%. This observation suggests
that long-term graft patency is not always necessary for
a successful outcome in patients with diabetes, providing
that wound healing precedes graft failure.
A meta-analysis of crural angioplasty performed by the
same group reported comparable limb salvage rates of 93%
and 82% at 1 and 36 months respectively.42 As with surgical
bypass, long term patency is less relevant, providing wound
healing is achieved following an intervention. The devel-
opment of drug-eluting stents and balloons offers the
potential to reduce rates of re-stenosis following endovas-
cular therapy, however, there is currently insufﬁcient
evidence to support the use of these devices in patients
with DFU. Some contemporary series report a combined
surgical and endovascular approach to the problem of
inﬂow disease47 which may be most useful in patients with
concomitant SFA and distal arterial occlusive disease. A
hybrid approach is particularly attractive in patients with
limited availability of vein conduit, which may otherwise
necessitate the use of prosthetic grafts. We expect that
both endovascular and bypass techniques will remain
widely used and complementary in the foreseeable future.
PREVENTION OF ULCERATION/SCREENING
Foot examination focussing on the presence of peripheral
neuropathy, PAD and abnormal foot anatomy can predict
risk of developing a diabetic foot ulcer.10,48 Diverse risk
stratiﬁcation systems exist incorporating these and addi-
tional risk factors, although none has been universally
adopted (Table 1). In a Scottish study which stratiﬁed foot
ulcer risk in 3526 patients with diabetes, foot ulceration
was 83 times more common in high-risk patients, compared
with low-risk patients.49 During a mean follow-up duration
of 1.7 years, the risk of foot ulceration was 0.36% in low-risk
patients (64% of the population), 2.3% in moderate-risk
patients and 29.4% in high-risk patients. The negative
predictive value of a low-risk score may be useful inTable 1. Variables included in the diverse stratiﬁcation systems.
Stratiﬁcation Variables
DN PAD Foot deformity Pre
UTFRS90 U U U
IWGDF15 U U U U
SIGN10 U U U U
ADA91 U U U U
Boyko et al.92 U U
UTFRS: University of Texas Foot Risk Stratiﬁcation; IWGDF: Internationa
Guideline Network; ADA: American Diabetes Association; DN: diabetic
Adapted from Monteiro-Soares M, Boyko EJ, Ribeiro J, Ribeiro I, Dinis-Ribeiro
Diabetologia 2011;54:1190e1199.directing the resources of specialized foot clinics towards
the minority of patients at medium- or high-risk.
Primary care physicians in the UK undertake annual foot
checks and stratify patients with diabetes according to their
risk of ulceration, however, the effectiveness of screening
programmes and complex interventions (education, podi-
atry, orthoses) in reducing both the risk of foot ulceration
and mortality is difﬁcult to conﬁrm.50,51 While the evidence
for speciﬁc interventions is sparse, it is clear that patients
with an established diabetic foot ulcer beneﬁt from prompt
recognition and early referral to a limb salvage team.
Following the introduction of a multidisciplinary foot team
at Ipswich hospital, UK, Krishnan et al. observed a 62%
reduction in major amputations in a catchment general
population.3 Larger ulcers are more difﬁcult to manage
hence the need for early identiﬁcation and intervention;
data from another established foot clinic demonstrated
a direct relationship between cross-sectional area (and
ulcer duration) at ﬁrst assessment and time to healing.52
Despite the prognostic performance of neuropathy and
PAD in predicting ulceration, a risk stratiﬁcation tool that
uses routinely available demographic and clinical data
would be more practical on a population level. The training
required for accurate clinical assessment of PAD and
neuropathy may not be feasible outside well-resourced
settings. Reallocating resources towards evidence based
multidisciplinary foot clinics may offer a better alternative
to primary care-led screening.
MEDICAL OPTIMIZATION
DM is recognized as a key risk factor for the development of
cardiovascular disease (CVD) and mortality from CVD causes
isz2-fold higher compared with individuals without DM.53
Recent evidence suggests that a history of foot ulceration
may increase this risk further still, showing excess all-cause
mortality in patients with DFU, compared with patients with
diabetes without a history of DFU.54 Accordingly, the
beneﬁts of CVD risk modiﬁcation in reducing morbidity and
mortality have been shown in populations with diabetes
and DFU.
The Steno-2 study randomized patients with type 2 dia-
betes and persistent microalbuminaemia to intensive CV
risk management, which corresponded to an absolute risk
reduction for all-cause mortality of 20% after a mean follow
up of 13.3 years (7.8 years of multifactorial intervention andvious ulcer Previous amputation Visual impairment
U
U
U U
U
U U
l Working Group on the Diabetic Foot; SIGN: Scottish Intercollegiate
neuropathy; PAD: peripheral arterial disease.
M. Risk stratiﬁcation systems for diabetic foot ulcers: a systematic review.
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selected for the presence of microalbuminuria which is
associated with microvascular disease and therefore
neuropathy and ulceration, and is itself a strong predictor of
CV events.56,57 In the setting of patients with DFU, Young
et al. reported improved survival of patients treated with
intensive CV risk modiﬁcation.58 In a foot clinic population,
5-year mortality fell from 48% to 27% following introduction
of a protocol incorporating CV risk screening and adminis-
tration of an antiplatelet agent, statin and antihypertensive
where indicated (level II evidence).
No direct evidence supports a role for tight glycaemic
control in preventing ulceration, although epidemiological
data suggests that optimizing blood glucose levels can
prevent peripheral neuropathy and PAD in patients with
diabetes. In the UK Prospective Diabetes Study, a reduction
in HbA1C of 1% was associated with a reduction in risk of
43% for amputation or death from PAD.59 Similarly, there
are no data to support aggressive glycaemic control to aid
healing in active ulceration; however this is also likely to be
important, not least because raised blood glucose encour-
ages infection. Strict glycaemic control will increase the risk
of hypoglycaemic attacks and weight gain in some patients.
In the majority of frail and elderly patients with DFU, less
intensive glycaemic goals are probably indicated, with
target blood glucose levels between 6 and 10 mmol/l.
ULCER/WOUND MANAGEMENT AND DRESSINGS
The quality of published reports supporting the use of local
interventions in DFU is poor but some principles guiding
foot care can be derived from the available literature.60,61
The cornerstone of early management in neuropathic
ulcers is ofﬂoading pressure with appropriate footwear,
removable devices or total contact casts (TCCs). The efﬁcacy
of prescribed footwear and removable devices is dependent
on patient compliance and, probably for this reason, the
TCC has demonstrated superior results in randomized
trials,62 and is recommended by the IWGDF as ﬁrst-choice
treatment.63 A perception of increased risk of falls with
TCCs appears to be unfounded.64,65 Despite all this, only
18% of approximately 600 patients with a plantar foot ulcer
in the Eurodiale study were treated with TCCs.36 Callus
formation contributes to abnormal loading and failure to
heal, and debridement should be routinely provided by
trained podiatrists. Evidence suggests that removal of
calluses is beneﬁcial for reducing plantar pressures,66,67
although this has yet to be conﬁrmed in randomized trials.
Despite their widespread use there is a paucity of
evidence to support the use of topical therapies for dia-
betic foot ulcers. In agreement with the conclusions of an
earlier Cochrane review,68 the IWGDF identiﬁed no good
quality randomized controlled trials (RCTs) reporting heal-
ing rate or infection outcomes from which to produce
clinical guidelines.60 The application of factors which aim to
promote healing by altering cell biology have failed to
demonstrate consistent efﬁcacy and there is insufﬁcient
evidence to justify the use of these expensive agents in
routine practice. Bioengineered skin grafts havedemonstrated favourable results in a prospective RCT
involving more than 300 patients receiving a dermal
ﬁbroblast culture69 A greater proportion of patients
receiving the bioengineered skin achieved complete heal-
ing at 12 weeks (30% vs 18%) compared with conventional
therapy (dressings, ofﬂoading footwear and debridements),
however the healing rates in the control group were lower
than expected. Although negative pressure wound therapy
(NPWT) is widely used in the treatment of chronic wounds,
much of the supporting evidence is based on industry
funded trials and unpublished data are largely inacces-
sible.70 One well-designed, industry supported RCT of 342
patients with an ulcer >2 cm2 reported promising
outcomes.71 NPWT was associated with reduced time to
wound closure, increased incidence of healing by 16 weeks
and reduced incidence of minor amputation. Further study
is, however, needed to justify the use of NPWT in routine
clinical practice. The evidence to support the use of
a particular dressing or topical therapy for the ulcer bed is
thin. Providing a comprehensive environment to improve
healing with antibiotics, debridement and ofﬂoading is
superior to the use of a novel, and often expensive,
dressing. It is what you take off the wound and not what
you put on it that counts.INFECTION/ANTIBIOTICS
The risk of infection in the diabetic foot increases with the
presence of PAD, recurrent or chronic wounds and those
penetrating to bone.72 The majority of infections are con-
tained within the soft tissue, but around a ﬁfth involve
underlying bone (osteomyelitis) which is associated with
a worse outcome. The diagnosis of diabetic foot infection is
based on clinical ﬁndings; superﬁcial wound cultures are not
useful and should not be treated, as bacterial colonization
appears to be ubiquitous in diabetic foot ulcers. Bone biopsy
for histopathology and culture remains the “gold standard”
for diagnosing osteomyelitis, yet unfortunately this proce-
dure is not routinely performed in clinical practice.73
Infection of a foot ulcer can be a major threat to limb and
life and should be treated promptly. The IWGDF has
produced guidelines for the treatment of diabetic foot
infections based on the severity of infection,28 which
predicts amputation. Ulcers with superﬁcial infection should
be treated with debridement and oral antibiotics aimed at
Staphylococcus aureus and streptococci. Targeted therapy
against gram positive cocci has been shown to be equally
effective as broader spectrum regimens (level I evidence),74
even in the presence of osteomyelitis which will respond to
antimicrobial therapy in most cases. Deep infection, char-
acterized by purulent discharge or fullness in the plantar
space,75 necessitates urgent debridement of necrotic tissue
including infected bone, and revascularisation if indicated.
Intravenous broad-spectrum antibiotics should target Gram-
positive and negative micro-organisms, including anaer-
obes. Signs of life and limb threatening infection include
bullae, ecchymoses, soft tissue crepitus and rapid spread of
infection.76
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edly negative impact of infection on ulcer healing that was
conﬁned to patients with PAD. These ﬁndings emphasize
the need for studies comparing different antibiotic regi-
mens in PAD and for those investigating the effects of early
revascularisation on control of infection.77
CLASSIFICATION AND OUTCOMES (REPORTING)
In studies of outcome following lower limb revascularisation
for critical limb ischaemia (CLI), patients with and without
diabetes are typically reported as one group. The unique
characteristics of PAD in diabetes, in its distribution and
presentation, make it difﬁcult to extrapolate clinical signif-
icance from data on unselected patients. Additionally, CLI
remains a problematic deﬁnition in patients with diabetes
as symptoms of ischaemic pain (claudication, rest pain) may
be masked by the presence of distal symmetric poly-
neuropathy, and ulceration may develop with very mild PAD
of little haemodynamic signiﬁcance. In contrast, patients
without diabetes are unlikely to develop tissue loss in the
absence of a severe perfusion deﬁcit. A haemodynamic
classiﬁcation of PAD using ankle brachial index (ABI), toe
pressures or transcutaneous oxygen tension is more useful
in patients with diabetes with the caveat that ABIs may be
falsely elevated due to arterial calciﬁcation and have a poor
predictive value. Patients with diabetes need to be identi-
ﬁed as an important subgroup in the PAD literature to allow
pooling of results for systematic review and meta-analysis.
Several angiographic classiﬁcation schemes exist to
describe the anatomical distribution of disease in patients
with PAD. The limitations of the currently available schemes
may, in part, explain the poor reporting of PAD distribution in
the literature. The Trans-Atlantic Inter-Society Consensus
(TASC) guidelines classify femoral popliteal lesions based on
their anatomical distribution,78 however, the classiﬁcation of
infrapopliteal lesions is not speciﬁcally addressed. This is
signiﬁcant given that the patency of the outﬂow artery is
critical in determining the success of arterial bypass, and this
is especially true in diabetes where run-off is more likely to be
poor. The Bollinger score,79,80 albeit more cumbersome
clinically, describes the infrapopliteal arterial segments in
some detail and is advantageous in this respect. In the BASIL
trial, below knee Bollinger scores were signiﬁcantly greater in
patients presenting with tissue loss; however the same
difference in above knee scores was not signiﬁcant. Inter-
estingly there was a negative correlation between mean
above and below knee Bollinger scores, suggesting that the
TASC score, in its current form, may underestimate disease
severity in a cohort of patients with diabetes and relative
sparing of the above knee arterial segments.
Several validated scoring systems have been developed
for use in diabetic foot ulcers. These include the University
of Texas Wound Classiﬁcation system and the Size (Area and
Depth), Sepsis, Arteriopathy, and Denervation (S(AD)SAD)
score,81,82 the latter of which has been prospectively vali-
dated in different ethnic groups and is a reliable predictor of
healing.83 The PEDIS score of the International WorkingGroup on the Diabetic Foot (IWDGF) was developed for
research purposes,84 but the grading of infection in this
system according to its severity is also advocated for clinical
use as it predicts outcome.85 A universal classiﬁcation
system of diabetic foot ulcers would enable consistent
reporting among studies in DFU to guide the development
of novel therapies while increasing the external validity of
research in this ﬁeld and allowing fair comparison between
centres.86 To this end the European Wound Management
Association (EMWA) has produced a set of recommenda-
tions for standardized reporting of outcomes in studies of
wound management.87 Clearly there will be some overlap
with the Society for Vascular Surgery standard reporting
criteria for the lower limb ischaemia,88 although some
important outcomes may be distinct. Ulcer healing has been
shown to be of particular importance to patients with
diabetes and is associated with improvements in health-
related quality of life (HRQOL).89 One study demonstrated
improvements in QOL in both the patient and caregiver
following ulcer healing.90
In a study of 449 patients with an index diabetic foot ulcer,
Jeffcoate et al. demonstrated how the use of ulcer-related
endpoints may underestimate morbidity and mortality in
this cohort.15 At 12 months, ulcer healing without amputa-
tion was achieved in 65.7% whereas only 45% of patients
were alive, without amputation and ulcer free. The authors
suggest that ulceration free survival may merit further
exploration as an outcome measure in diabetic foot disease.
The balance of risk and beneﬁt for interventions in diabetic
foot disease is probably best assessed through a combina-
tion of deﬁned clinical endpoints including mortality,
amputation-free survival, healing and re-ulceration with
patient-reported outcome measures.
FUTURE PERSPECTIVES
Better selection of patients for revascularisation procedures
will rely on improvements in the reporting of outcome in
diabetic foot disease. Whilst new data on the impact of
revascularisation are awaited, there are encouraging
developments in other treatment modalities, including
stem cell and progenitor cell therapy. As discussed previ-
ously, PAD is present in around half of patients with DFU.
The impact of PAD on wound healing is compounded by
impaired formation of new capillaries (angiogenesis) and
proliferation of pre-existing micro-vessels into collateral
arteries (arteriogenesis) in patients with diabetes. Stimula-
tion of angiogenesis and arteriogenesis represent attractive
approaches in DFU and there is accumulating evidence to
conﬁrm their efﬁcacy in the treatment of critical limb
ischaemia.91 Pooled data from studies of autologous bone
marrow mononuclear cell (BMMNC) therapy in patients
with PAD show increases in ABI values between 0.1 and 0.2
points, TcPO2 increases between 10 and 20 mmHg O2 and
improvements in walking distances. Although data in
selected populations with DFU are limited, one study in
China demonstrated improved ulcer healing rates with
BMMNCs and bone marrow mesenchymal stem cells
J.R.W. Brownrigg et al. 679compared with controls.92 Further research should clarify
the role of cell therapies in DFU.CONCLUSIONS
The present review underlines the difﬁculty in diagnosing
PAD in patients with diabetes and the importance of referring
those presenting with a new foot ulcer to a multidisciplinary
team, which includes vascular surgeons and interventional
radiologists. Interventions should aim not only to preserve
limb, but also attenuate the excess mortality observed in
patients with diabetic foot disease; there is likely an unmet
potential for CVD prevention in this cohort.
The role of population based screening to identify those at
risk of developing ulceration remains unclear and the
evidence for interventions in this high risk population derives
from studies of poor methodological quality. The develop-
ment of future clinical guidelines will rely on selective
reporting of relevant outcomes in patients with diabetes
following lower limb revascularisation. Patients with diabetes
represent a distinct and important sub-group because they
behave differently to non-diabetics in almost all respects.CONFLICT OF INTEREST/FUNDING
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